Brookline Capital Markets Starts Adial Pharmaceuticals Inc (ADIL) at Buy

October 13, 2021 9:29 AM EDT
Get Alerts ADIL Hot Sheet
Price: $3.26 -1.21%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 12 | New: 18
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Brookline Capital Markets analyst Kumaraguru Raja initiates coverage on Adial Pharmaceuticals Inc (NASDAQ: ADIL) with a Buy rating and a price target of $12.00.

The analyst commented, "We are initiating coverage of Adial Pharmaceuticals with a Buy rating and a Price Target of $12. Adial Pharmaceuticals is developing AD04 for alcohol use disorder (AUD). AD04 is in the Phase 3 ONWARD trial with data expected in 1H 2022. In multiple Phase 2 trials AD04 was safe and efficacious. The adenosine platform is advancing in preclinical testing as multiple analogues are being developed for a non-opioid pain program. We expect cash to fund operations into early 2022. We foresee a favorable risk reward as AD04 and the adenosine analogs advance through the clinic."

For an analyst ratings summary and ratings history on Adial Pharmaceuticals Inc click here. For more ratings news on Adial Pharmaceuticals Inc click here.

Shares of Adial Pharmaceuticals Inc closed at $3.74 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage